The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

72 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
cis-1-Oxo-heterocyclyl-4-amido cyclohexane derivatives as NPY5 receptor antagonists.EBI
Lundbeck Research Usa
Ligands of the neuropeptide Y Y2 receptor.EBI
The Scripps Research Institute
Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications.EBI
University Of Copenhagen
Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.EBI
University Of Regensburg
Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane β-amino acids shifts selectivity toward the Y(4) receptor.EBI
University Of Regensburg
The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.EBI
Glaxosmithkline
Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.EBI
Glaxosmithkline
Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists.EBI
Glaxosmithkline
Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.EBI
Pfizer
Indolyl and dihydroindolyl N-glycinamides as potent and in vivo active NPY5 antagonists.EBI
Lundbeck Research Usa
Discovery of novel orally active ureido NPY Y5 receptor antagonists.EBI
Schering-Plough Research Institute
Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.EBI
Taisho Pharmaceutical
N-(sulfonamido)alkyl[tetrahydro-1H-benzo[e]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor.EBI
The R. W. Johnson Pharmaceutical Research Institute
5-(2'-Pyridyl)-2-aminothiazoles: alkyl amino sulfonamides and sulfamides as potent NPY(5) antagonists.EBI
Lundbeck Research Usa
Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.EBI
Lundbeck Research Usa
N-Heteroaryl glycinamides and glycinamines as potent NPY5 antagonists.EBI
Lundbeck Research Usa
Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.EBI
Tsukuba Research Institute
Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.EBI
Universit£T Regensburg
Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.EBI
Pfizer
Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.EBI
Glaxosmithkline
Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists.EBI
Schering-Plough Research Institute
Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.EBI
Tsukuba Research Institute
Identification of positron emission tomography ligands for NPY Y5 receptors in the brain.EBI
Tsukuba Research Institute
Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors.EBI
Tsukuba Research Institute
Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.EBI
Tsukuba Research Institute
The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.EBI
Glaxosmithkline
Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.EBI
Tsukuba Research Institute
Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.EBI
Tsukuba Research Institute
Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists.EBI
Tsukuba Research Institute
Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.EBI
Tsukuba Research Institute
Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.EBI
University Of Regensburg
Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.EBI
Banyu Tsukuba Research Institute
Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.EBI
Banyu Tsukuba Research Institute
(9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.EBI
Tsukuba Research Institute
Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice.EBI
Bayer Pharmaceuticals
A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice.EBI
Bayer Pharmaceuticals
Identification of selective neuropeptide Y2 peptide agonists.EBI
Bayer Pharmaceuticals
Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1.EBI
Taisho Pharmaceutical
Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.EBI
Novartis Pharma
Synthesis of new thiophene and benzo[b]thiophene hydrazide derivatives as human NPY Y(5) antagonists.EBI
Universidad De Navarra
Structure-activity relationship studies on 2-heteroaryl-4-arylimidazoles NPY5 receptor antagonists.EBI
Pfizer
Structure-activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteres.EBI
Pfizer
In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist.EBI
Pfizer
Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists.EBI
Tsukuba Research Institute
Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity.EBI
Astrazeneca
High-throughput synthesis optimization of sulfonamide NPY Y5 antagonists.EBI
Lundbeck Research Usa
Discovery of potent and selective small molecule NPY Y5 receptor antagonists.EBI
Lundbeck Research Usa
Novel potent antagonists of human neuropeptide Y Y5 receptor. Part 1: 2-oxobenzothiazolin-3-acetic acid derivatives.EBI
Fujisawa Pharmaceutical
Novel potent antagonists of human neuropeptide Y-Y5 receptor. Part 4: tetrahydrodiazabenzazulene derivatives.EBI
Fujisawa Pharmaceutical
Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives.EBI
Fujisawa Pharmaceutical
Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 2: substituted benzo[a]cycloheptene derivatives.EBI
Fujisawa Pharmaceutical
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.EBI
The R. W. Johnson Pharmaceutical Research Institute
Aminopyrazoles with high affinity for the human neuropeptide Y5 receptor.EBI
The R. W. Johnson Pharmaceutical Research Institute
Synthesis and structure-activity relationships of trisubstituted phenyl urea derivatives as neuropeptide Y5 receptor antagonists.EBI
Amgen
Oligopeptides as Neuropeptide Y YEBI
University Of Regensburg
Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90).EBI
University Of Cincinnati And Va Medical Centers
Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists.EBI
Amgen
High Affinity Agonists of the Neuropeptide Y (NPY) Y4 Receptor Derived from the C-Terminal Pentapeptide of Human Pancreatic Polypeptide (hPP): Synthesis, Stereochemical Discrimination, and Radiolabeling.EBI
University Of Regensburg
N-acylated alpha-(3-pyridylmethyl)-beta-aminotetralin antagoinists of the human neuropeptide Y Y5 receptor.EBI
The R. W. Johnson Pharmaceutical Research Institute
Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.EBI
University Of Regensburg
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.EBI
Novartis Pharma
alpha-Substituted N-(sulfonamido)alkyl-beta-aminotetralins: potent and selective neuropeptide Y Y5 receptor antagonists.EBI
The R. W. Johnson Pharmaceutical Research Institute
Pharmacological treatment of obesity: therapeutic strategies.EBI
The R. W. Johnson Pharmaceutical Research Institute
Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists.EBI
Eli Lilly
N(?)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.EBI
Cnrs/Ipbs (Institut De Pharmacologie Et Biologie Structurale)
Design of YEBI
TBA
Identification and Characterization of the First Selective YEBI
Leipzig University
A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance.BDB
Massachusetts Institute Of Technology